Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival
Patients with glioblastoma multiforme (GBM) are at high risk to develop a relapse despite multimodal therapy. Assumedly, glioma stem cells (GSCs) are responsible for treatment resistance of GBM. Identification of specific GSC markers may help to develop targeted therapies. Here, we performed express...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2018/9628289 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562858302373888 |
|---|---|
| author | Sandra Bien-Möller Ellen Balz Susann Herzog Laura Plantera Silke Vogelgesang Kerstin Weitmann Carolin Seifert Matthias A. Fink Sascha Marx Angela Bialke Chitra Venugopal Sheila K. Singh Wolfgang Hoffmann Bernhard H. Rauch Henry W. S. Schroeder |
| author_facet | Sandra Bien-Möller Ellen Balz Susann Herzog Laura Plantera Silke Vogelgesang Kerstin Weitmann Carolin Seifert Matthias A. Fink Sascha Marx Angela Bialke Chitra Venugopal Sheila K. Singh Wolfgang Hoffmann Bernhard H. Rauch Henry W. S. Schroeder |
| author_sort | Sandra Bien-Möller |
| collection | DOAJ |
| description | Patients with glioblastoma multiforme (GBM) are at high risk to develop a relapse despite multimodal therapy. Assumedly, glioma stem cells (GSCs) are responsible for treatment resistance of GBM. Identification of specific GSC markers may help to develop targeted therapies. Here, we performed expression analyses of stem cell (ABCG2, CD44, CD95, CD133, ELF4, Nanog, and Nestin) as well as differentiation and microglia markers (GFAP, Iba1, and Sparc) in GBM compared to nonmalignant brain. Furthermore, the role of these proteins for patient survival and their expression in LN18 stem-like neurospheres was analyzed. At mRNA level, ABCG2 and CD95 were reduced, GFAP was unchanged; all other investigated markers were increased in GBM. At protein level, CD44, ELF4, Nanog, Nestin, and Sparc were elevated in GBM, but only CD133 and Nestin were strongly associated with survival time. In addition, ABCG2 and GFAP expression was decreased in LN18 neurospheres whereas CD44, CD95, CD133, ELF4, Nanog, Nestin, and Sparc were upregulated. Altogether only CD133 and Nestin were associated with survival rates. This raises concerns regarding the suitability of the other target structures as prognostic markers, but makes both CD133 and Nestin candidates for GBM therapy. Nevertheless, a search for more specific marker proteins is urgently needed. |
| format | Article |
| id | doaj-art-218f53324488424fa91fe360416fe654 |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-218f53324488424fa91fe360416fe6542025-02-03T01:21:37ZengWileyStem Cells International1687-966X1687-96782018-01-01201810.1155/2018/96282899628289Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient SurvivalSandra Bien-Möller0Ellen Balz1Susann Herzog2Laura Plantera3Silke Vogelgesang4Kerstin Weitmann5Carolin Seifert6Matthias A. Fink7Sascha Marx8Angela Bialke9Chitra Venugopal10Sheila K. Singh11Wolfgang Hoffmann12Bernhard H. Rauch13Henry W. S. Schroeder14Department of Pharmacology, University Medicine Greifswald, Greifswald, GermanyDepartment of Pharmacology, University Medicine Greifswald, Greifswald, GermanyDepartment of Neurosurgery, University Medicine Greifswald, Greifswald, GermanyDepartment of Neurosurgery, University Medicine Greifswald, Greifswald, GermanyDepartment of Neuropathology, Institute of Pathology, University Medicine Greifswald, Greifswald, GermanyInstitute for Community Medicine, University Medicine Greifswald, Greifswald, GermanyDepartment of Pharmacology, University Medicine Greifswald, Greifswald, GermanyDepartment of Pharmacology, University Medicine Greifswald, Greifswald, GermanyDepartment of Pharmacology, University Medicine Greifswald, Greifswald, GermanyTrusted Third Party, University Medicine Greifswald, Greifswald, GermanyMcMaster University Hamilton, McMaster Stem Cell and Cancer Research Institute, Hamilton, ON, CanadaMcMaster University Hamilton, McMaster Stem Cell and Cancer Research Institute, Hamilton, ON, CanadaInstitute for Community Medicine, University Medicine Greifswald, Greifswald, GermanyDepartment of Pharmacology, University Medicine Greifswald, Greifswald, GermanyDepartment of Neurosurgery, University Medicine Greifswald, Greifswald, GermanyPatients with glioblastoma multiforme (GBM) are at high risk to develop a relapse despite multimodal therapy. Assumedly, glioma stem cells (GSCs) are responsible for treatment resistance of GBM. Identification of specific GSC markers may help to develop targeted therapies. Here, we performed expression analyses of stem cell (ABCG2, CD44, CD95, CD133, ELF4, Nanog, and Nestin) as well as differentiation and microglia markers (GFAP, Iba1, and Sparc) in GBM compared to nonmalignant brain. Furthermore, the role of these proteins for patient survival and their expression in LN18 stem-like neurospheres was analyzed. At mRNA level, ABCG2 and CD95 were reduced, GFAP was unchanged; all other investigated markers were increased in GBM. At protein level, CD44, ELF4, Nanog, Nestin, and Sparc were elevated in GBM, but only CD133 and Nestin were strongly associated with survival time. In addition, ABCG2 and GFAP expression was decreased in LN18 neurospheres whereas CD44, CD95, CD133, ELF4, Nanog, Nestin, and Sparc were upregulated. Altogether only CD133 and Nestin were associated with survival rates. This raises concerns regarding the suitability of the other target structures as prognostic markers, but makes both CD133 and Nestin candidates for GBM therapy. Nevertheless, a search for more specific marker proteins is urgently needed.http://dx.doi.org/10.1155/2018/9628289 |
| spellingShingle | Sandra Bien-Möller Ellen Balz Susann Herzog Laura Plantera Silke Vogelgesang Kerstin Weitmann Carolin Seifert Matthias A. Fink Sascha Marx Angela Bialke Chitra Venugopal Sheila K. Singh Wolfgang Hoffmann Bernhard H. Rauch Henry W. S. Schroeder Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival Stem Cells International |
| title | Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival |
| title_full | Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival |
| title_fullStr | Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival |
| title_full_unstemmed | Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival |
| title_short | Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival |
| title_sort | association of glioblastoma multiforme stem cell characteristics differentiation and microglia marker genes with patient survival |
| url | http://dx.doi.org/10.1155/2018/9628289 |
| work_keys_str_mv | AT sandrabienmoller associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT ellenbalz associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT susannherzog associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT lauraplantera associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT silkevogelgesang associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT kerstinweitmann associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT carolinseifert associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT matthiasafink associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT saschamarx associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT angelabialke associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT chitravenugopal associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT sheilaksingh associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT wolfganghoffmann associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT bernhardhrauch associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival AT henrywsschroeder associationofglioblastomamultiformestemcellcharacteristicsdifferentiationandmicrogliamarkergeneswithpatientsurvival |